Shares of InterMune (ITMN -12.5%) add to yesterday's selloff after the Institute for Quality and...

|By:, SA News Editor

Shares of InterMune (ITMN -12.5%) add to yesterday's selloff after the Institute for Quality and Efficiency in Health Care concluded that no additional benefit could be found for its idiopathic pulmonary fibrosis drug Esbriet, also known as pirfenidone.